Biofrontera AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DE0006046113
EUR
2.55
-0.33 (-11.3%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.25 k

Shareholding (Mar 2021)

FII

1.45%

Held by 1 FIIs

DII

98.55%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 15 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.22

stock-summary
Return on Equity

-5.68%

stock-summary
Price to Book

1.05

Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Sep 2025)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.3%
0%
-11.3%
6 Months
-11.3%
0%
-11.3%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Biofrontera AG for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-6.78%
EBIT Growth (5y)
14.52%
EBIT to Interest (avg)
-2.18
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
1.07
Tax Ratio
55.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.45%
ROCE (avg)
7.72%
ROE (avg)
11.71%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.06
EV to EBIT
-12.80
EV to EBITDA
12.80
EV to Capital Employed
1.08
EV to Sales
0.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2.22%
ROE (Latest)
-5.68%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2021stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (1.45%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 20.00% vs -48.28% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 90.91% vs -728.57% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.60",
          "val2": "3.00",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.80",
          "val2": "0.60",
          "chgp": "-233.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.40",
          "val2": "-4.40",
          "chgp": "90.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-281.70%",
          "val2": "111.20%",
          "chgp": "-39.29%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -32.61% vs 25.29% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -975.00% vs 99.10% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "21.70",
          "val2": "32.20",
          "chgp": "-32.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.10",
          "val2": "5.60",
          "chgp": "-191.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-0.40",
          "chgp": "-975.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-274.30%",
          "val2": "148.30%",
          "chgp": "-42.26%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
3.60
3.00
20.00%
Operating Profit (PBDIT) excl Other Income
-0.80
0.60
-233.33%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.40
-4.40
90.91%
Operating Profit Margin (Excl OI)
-281.70%
111.20%
-39.29%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 20.00% vs -48.28% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 90.91% vs -728.57% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
21.70
32.20
-32.61%
Operating Profit (PBDIT) excl Other Income
-5.10
5.60
-191.07%
Interest
0.00
0.00
Exceptional Items
-1.30
0.00
Consolidate Net Profit
-4.30
-0.40
-975.00%
Operating Profit Margin (Excl OI)
-274.30%
148.30%
-42.26%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -32.61% vs 25.29% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -975.00% vs 99.10% in Dec 2023

stock-summaryCompany CV
About Biofrontera AG stock-summary
stock-summary
Biofrontera AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available